|
|
Article: Dynavax Announces Interim Analysis From Ragweed Allergy Phase 2/3 Trial.
- Article from:
- PR Newswire
- Article date:
- December 20, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Positive Trends Relative to Primary and Secondary Endpoints Demonstrated
Dynavax Technologies announced that the one-year interim analysis of the company's two-year Phase 2/3 clinical trial of its ragweed allergy ISS-based therapeutic (AIC, or Amb a 1 ISS conjugate) showed a clear positive trend relative to the trial's major endpoint of nasal symptom scores, as well as other secondary endpoints, following the 2004 ragweed season. The interim analysis indicated that AIC was safely administered and systemic adverse reactions were similar between the AIC and control arms.
Dynavax intends to complete the two-year clinical trial as planned, a decision that ...